Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Benitec Biopharma (BNTC) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Benitec Biopharma (BNTC) over the last 7 years, with Q1 2025 value amounting to $426000.0.

  • Benitec Biopharma's Accumulated Expenses fell 1760.15% to $426000.0 in Q1 2025 from the same period last year, while for Mar 2025 it was $426000.0, marking a year-over-year decrease of 1760.15%. This contributed to the annual value of $475000.0 for FY2024, which is 63.56% up from last year.
  • As of Q1 2025, Benitec Biopharma's Accumulated Expenses stood at $426000.0, which was down 1760.15% from $537000.0 recorded in Q4 2024.
  • In the past 5 years, Benitec Biopharma's Accumulated Expenses registered a high of $537000.0 during Q4 2024, and its lowest value of $231000.0 during Q1 2021.
  • Over the past 5 years, Benitec Biopharma's median Accumulated Expenses value was $426000.0 (recorded in 2025), while the average stood at $411823.5.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 5454.55% in 2022, then tumbled by 1760.15% in 2025.
  • Quarter analysis of 5 years shows Benitec Biopharma's Accumulated Expenses stood at $321000.0 in 2021, then grew by 23.36% to $396000.0 in 2022, then soared by 32.07% to $523000.0 in 2023, then rose by 2.68% to $537000.0 in 2024, then fell by 20.67% to $426000.0 in 2025.
  • Its Accumulated Expenses stands at $426000.0 for Q1 2025, versus $537000.0 for Q4 2024 and $495000.0 for Q3 2024.